PLCE1 gene might affect osteosarcoma immune status

The First Affiliated Hospital of Guangxi Medical University

Although considerable advances have been made in the clinical treatment of osteosarcoma (OS), a type of bone cancer, the overall survival rate of OS patients has not significantly increased. In order to expand the choices for the clinical diagnosis and treatment of OS, it is necessary to investigate molecular mechanisms and identify novel therapeutic targets.

Using the immunohistochemistry method, researchers from the Wuming Hospital of Guangxi Medical University and the First Affiliated Hospital of Guangxi Medical University analyzed PLCE1 gene and its expression in osteosarcoma and normal bone tissue. After exploring the relationship between PLCE1 and immune genes and examining the biological function of PLCE1 in osteosarcoma, they came to a conclusion that its expression in osteosarcoma tissue was higher than that in normal bone tissue. Furthermore, assays found that PLCE1 may promote immune escape from osteosarcoma by CD70-CD27 signaling pathway. Silencing this gene brings certain behaviors of OS cells: it promotes cell death, inhibits cell growth and division, and prevents cell migration and invasion.

Based on the results, researchers concluded that PLCE1 is a poor prognostic marker and may be a potential key factor affecting the immune status of OS tumor microenvironment.

尽管骨肉瘤 (OS) 在临床治疗中取得了很大的进展,但 OS 患者的总体生存率并未显着提高。为了扩大OS临床诊断和治疗的选择,有必要研究分子机制并确定新的治疗靶点。
广西医科大学武鸣医院和广西医科大学第一附属医院的研究人员采用免疫组织化学方法分析了PLCE1基因及其在骨肉瘤和正常骨组织中的表达情况。在探索PLCE1与免疫基因的关系,检测PLCE1在骨肉瘤中的生物学功能后,他们得出结论,其在骨肉瘤组织中的表达高于在正常骨组织中的表达。此外,分析发现 PLCE1 可能通过 CD70-CD27 信号通路促进骨肉瘤的免疫逃逸。沉默该基因能够促进OS细胞发生凋亡,细胞生长和分化受到抑制,细胞迁移和侵袭能力受阻。
基于以上结果,研究人员得出结论:PLCE1是一种不良预后标志物,可能是影响OS肿瘤微环境免疫状态的潜在关键因素。

 

Reference: Huang L, Liao C, Wu H, Huang P. PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway. Bosn J of Basic Med Sci [Internet]. 2022Jun.26 [cited 2022Jun.27];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7416

Editor: Merima Bukva, MPharm

Be the first to comment

Leave a Reply